MyFinsight
Home
Blog
About
Proceeds from sales and
maturities of investments
$26,964K
(-70.40%↓ Y/Y)
Proceeds from issuance of
common stock, net
$9,075K
Net cash provided by
investing activities
$18,260K
(-49.09%↓ Y/Y)
Net cash provided by
financing activities
$9,075K
Canceled cashflow
$8,704K
Net (decrease)
increase in cash, cash...
-$2,291K
(-180.50%↓ Y/Y)
Canceled cashflow
$27,335K
Accounts payable
$4,810K
(1044.99%↑ Y/Y)
Stock-based compensation
expense
$1,806K
(-44.89%↓ Y/Y)
Prepaid expenses and
other current assets
-$150K
(-106.47%↓ Y/Y)
Operating right-of-use
assets and operating...
-$78K
Depreciation expense
$51K
(-61.94%↓ Y/Y)
Other
-$10K
(-103.46%↓ Y/Y)
Purchases of investments
$8,698K
(-84.25%↓ Y/Y)
Purchases of property and
equipment
$6K
Net cash used in
operating activities
-$29,626K
(10.28%↑ Y/Y)
Canceled cashflow
$6,905K
Net loss
-$35,037K
(-1.15%↓ Y/Y)
Accrued expenses
-$1,268K
(-157.01%↓ Y/Y)
Net amortization of
premiums and discounts on...
$226K
(-63.78%↓ Y/Y)
Back
Back
Cash Flow
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
source: myfinsight.com